Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: The Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV)

Circulation

Volumn 125, Issue 10, 2012, Pages 1246-1255

  Jensen, Lisette Okkels ^a   Thayssen, Per ^a   Hansen, Henrik Steen ^a   Christiansen, Evald Høj ^b   Tilsted, Hans Henrik ^c   Krusell, Lars Romer ^b   Villadsen, Anton Boel ^c   Junker, Anders ^a   Hansen, Knud Nørregaard ^a   Kaltoft, Anne ^b   Maeng, Michael ^b   Pedersen, Knud Erik ^a   Kristensen, Steen Dalby ^b   Bøtker, Hans Erik ^b   Ravkilde, Jan ^c   Sanchez, Richardo ^d   Aarøe, Jens ^c   Madsen, Morten ^b   Sørensen, Henrik Toft ^b   Thuesen, Leif ^b   Lassen, Jens Flensted ^b   more..

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d Heart Center Varde   (Denmark)

Author keywords

Drug eluting stent; Revascularization; Treatment outcome

Indexed keywords

CYPHER; EVEROLIMUS; RAPAMYCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RISK FACTORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84858377141     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.063644     Document Type: Article

References (32)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780. (Pubitemid 34586912)
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323. (Pubitemid 37186209)
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231. (Pubitemid 38067635)
4. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-678. (Pubitemid 46281313)
5. Jensen LO, Tilsted HH, Thayssen P, Kaltoft A, Maeng M, Lassen JF, Hansen KN, Madsen M, Ravkilde J, Johnsen SP, Sorensen HT, Thuesen L. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention. 2010;5:898-905.
6. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrom T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrom SZ, Aaroe J, Jensen JS, Kristensen SD, Botker HE, Madsen M, Johnsen SP, Jensen LO, Sorensen HT, Thuesen L, Lassen JF. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet. 2010;375:1090-1099.
7. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxeleluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-209.
8. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-1913. (Pubitemid 351574920)
9. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Dimario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimuseluting coronary stents. N Engl J Med. 2010;363:136-146.
10. Jensen LO, Thayssen P, Tilsted HH, Ravkilde J, Junker A, Hansen HS, Hansen KN, Pedersen KE, Sorensen HT, Thuesen L, Lassen JF. rationale and design of a randomized clinical comparison of everolimus-eluting (Xience V/Promus) and sirolimus-eluting (Cypher Select+) coronary stents in unselected patients with coronary heart disease. Cardiology. 2010;116:73-78.
11. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268. (Pubitemid 29299976)
12. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Soerensen HT, Thuesen L. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007;50:463-470. (Pubitemid 47088133)
13. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull. 1999;46:354-357. (Pubitemid 29439149)
14. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1-e37.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
16. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-2538. (Pubitemid 47616190)
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. (Pubitemid 17055592)
18. Frank L. Epidemiology; when an entire country is a cohort. Science. 2000;287:2398-2399. (Pubitemid 30185417)
19. Galloe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamaki K, Junker A, Aaroe J, Abildgaard U, Ravkilde J, Engstrom T, Jensen JS, Andersen HR, Botker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrom SZ, Stephansen GB, Lassen JF. Comparison of paclitaxel-and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008;299:409-416. (Pubitemid 351185949)
20. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9:1447-1454.
21. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP. Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006;295:895-904.
22. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948. (Pubitemid 47393576)
23. Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de LJ, Kaiser C, Park SJ, Goy JJ, Lee JH, Di LE, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1373-1380. (Pubitemid 47449734)
24. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-1674.
25. Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patientrelated versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet. 2011;377:1241-1247.
26. Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention. 2005;1:58-65.
27. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrie D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention. 2006;2:286-294.
28. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation. 2009;119:680-686.
29. Raber L, Juni P, Nuesch E, Kalesan B, Wenaweser P, Moschovitis A, Khattab AA, Bahlo M, Togni M, Cook S, Vogel R, Seiler C, Meier B, Windecker S. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol. 2011;57:2143-2151.
30. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, Di MC, Davies S, van Geuns RJ, Eerdmans P, Van Es GA, Meier B, Juni P. Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer for Coronary Revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163-1173.
31. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schomig A, Mehilli J. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30:2441-2449.
32. Ruygrok PN, Melkert R, Morel MA, Ormiston JA, Bar FW, Fernandez-Aviles F, Suryapranata H, Dawkins KD, Hanet C, Serruys PW. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol. 1999;34:1507-1511. (Pubitemid 29528665)